17.42
0.18 (1.04%)
| Previous Close | 17.24 |
| Open | 17.24 |
| Volume | 260,931 |
| Avg. Volume (3M) | 327,900 |
| Market Cap | 537,049,920 |
| Price / Sales | 1.82 |
| Price / Book | 0.460 |
| 52 Weeks Range | |
| Earnings Date | 1 May 2025 - 5 May 2025 |
| Profit Margin | -15.07% |
| Operating Margin (TTM) | -21.17% |
| Diluted EPS (TTM) | -1.41 |
| Quarterly Revenue Growth (YOY) | 8.10% |
| Total Debt/Equity (MRQ) | 0.82% |
| Current Ratio (MRQ) | 4.85 |
| Operating Cash Flow (TTM) | 21.06 M |
| Levered Free Cash Flow (TTM) | -25.57 M |
| Return on Assets (TTM) | -3.76% |
| Return on Equity (TTM) | -3.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bearish |
| Diagnostics & Research (Global) | Mixed | Bearish | |
| Stock | Fulgent Genetics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 32.76% |
| % Held by Institutions | 56.48% |
| 52 Weeks Range | ||
| Median | 16.00 (-8.15%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 04 Mar 2025 | 16.00 (-8.15%) | Hold | 15.52 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Apr 2025 | Announcement | Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025 |
| 07 Mar 2025 | Announcement | DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 |
| 28 Feb 2025 | Announcement | Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results |
| 06 Feb 2025 | Announcement | Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025 |
| 04 Feb 2025 | Announcement | Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |